NYSE$ELV

Elevance Health Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Anthem reported strong financial performance with double-digit top and bottom line growth.

Anthem, Inc. reported fourth quarter and full year 2021 results reflecting strong financial performance, including double-digit top and bottom line growth. Fourth quarter operating revenue grew by 14.2% to $36.0 billion, and medical enrollment increased by 303 thousand members to 45.4 million members.

  • Fourth quarter GAAP net income was $4.63 per share, including net negative adjustment items of $0.51 per share. Adjusted net income was $5.14 per share.
  • Full year GAAP net income was $24.73 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $25.98 per share.
  • Fourth quarter operating revenue grew by 14.2% over the prior year quarter to $36.0 billion.
  • Medical enrollment increased by 2.4 million members year-over-year and 303 thousand members in the fourth quarter to 45.4 million members.

Headline financials

Total Revenue

$36B

Previous: $31.5B+14.2%
EPS (adj)

$5.14

Previous: $2.54+102.4%
Total Medical Membership

45.4M

Previous: 42.9M+5.8%
Capital Expenditures

$340M

Previous: $278M+22.3%
Free Cash Flow

$1.33B

Previous: $3.54B-62.3%
Net Income

$1.13B

Previous: $551M+104.2%
Operating Income

$1.19B

Previous: $605M+96.4%
Gross Profit

$9.04B

Previous: $7.74B+16.9%
Cash & Equivalents

$4.88B

Previous: $5.74B-15.0%
Total Assets

$97.5B

Previous: $86.6B+12.5%
Stock-Based Comp

$59M

Previous: $69M-14.5%

Revenue & EPS history

Elevance Health · Revenue · Quarterly

$36B

Q4 2021+14.2%vs Q4 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Elevance Health · $36.7B total across 1 segment · Q3 2023

  • Health Benefits
    $36.7B

Forward guidance

Full year 2022 GAAP net income is expected to be greater than $26.75 per share. Adjusted net income is expected to be greater than $28.25 per share.

Tailwinds

  • GAAP net income is expected to be greater than $26.75 per share, including approximately $1.50 per share of net unfavorable items.
  • Adjusted net income is expected to be greater than $28.25 per share.
  • Medical membership is expected to be in the range of 45.6 - 46.2 million.
  • Operating revenue is expected to be approximately $152 billion, including premium revenue of approximately $130 billion.
  • Operating cash flow is expected to be greater than $6.9 billion.

Headwinds

  • Benefit expense ratio is expected to be in the range of 88.0% plus or minus 50 basis points.
  • SG&A ratio is expected to be 10.8% plus or minus 50 basis points.
  • Investment income is expected to be $1.1 billion.
  • Interest expense is expected to be $840 million.
  • Effective tax rate is expected to be between 22.0 - 24.0%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.4%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+11.1%

Q4 2018

Best reaction

-15.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.3%+8.5%+20.3%
Q4 2025+5.1%+5.9%-0.9%
Q3 2025-1.1%-3.3%-11.3%
Q2 2025+0.3%+6.0%+5.9%
Q1 2025+2.1%+3.7%-5.5%
Q4 2024+2.9%+3.8%-1.4%
Q3 2024-15.0%-15.5%-19.4%
Q2 2024-8.7%-8.9%-1.7%
Q1 2024+4.1%+4.7%+7.6%
Q4 2023+1.8%+3.0%+8.9%
Q3 2023-0.6%-3.0%-0.6%
Q2 2023+7.2%+6.2%+4.3%
Q1 2023-5.8%-4.2%-5.2%
Q4 2022+3.6%+2.2%-0.1%
Q3 2022+2.0%+10.1%+3.6%
Q2 2022-7.6%-5.3%+1.2%
Q1 2022+1.1%-2.0%-4.7%
Q4 2021-0.8%+0.4%+3.3%
Q3 2021+9.3%+10.4%+5.5%
Q2 2021-1.4%-2.9%-3.1%
Q1 2021-0.5%-1.1%+3.7%
Q4 2020-3.8%-6.4%-3.0%
Q3 2020-8.6%-6.9%+4.7%
Q2 2020+4.5%+2.1%+4.5%
Q1 2020+4.7%+1.0%+9.7%
Q4 2019-8.4%-8.2%-11.4%
Q3 2019-0.3%+2.9%+12.1%
Q2 2019-2.9%-1.4%-13.9%
Q1 2019+2.1%+6.2%+10.6%
Q4 2018+11.1%+11.6%+12.8%
Q3 2018+0.2%+1.4%+9.3%
Q2 2018+0.4%+2.5%+7.8%
Q1 2018+5.3%+4.9%+3.3%
Q4 2017+0.2%-5.3%-4.3%
Q3 2017+6.0%+7.3%+12.9%
Q2 2017-3.7%-2.3%+1.1%
Q1 2017+3.4%+3.9%+6.2%
Q4 2016+2.3%+1.7%+7.7%
Q3 2016+2.2%+5.2%+23.6%
Q2 2016-3.4%-7.3%-9.2%
Q1 2016-2.1%
Q4 2015-8.2%
Q3 2015-2.3%
Q2 2015+0.4%
Q1 2015-2.1%
Q4 2014-0.5%
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2011
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q3 2011
Q2 2011
Q1 2011
Q4 2010
Q3 2010
Q2 2010
Q1 2009
Q1 2010
Q4 2007
Q4 2009
Q3 2009
Q3 2008
Q4 2008
Q2 2009
Q2 2008

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro